Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS and BRAF: drug targets and predictive biomarkers.

The Journal of pathology - 1 Jan 2011

Vakiani Efsevia, Solit David B

Abstract excerpt

Three decades have passed since RAS was first identified as the transformative factor in the Harvey and Kirsten strains of the mouse sarcoma virus. RAS and several of its downstream effectors, including BRAF, have since been shown to be commonly mutated in broad range of human cancers and biological studies have confirmed that RAS pathway activation promotes tumour initiation, progression and metastatic spread in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasms

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 21125676
DOI: 10.1002/path.2796

Genes

BRAF
EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS and BRAF: drug targets and predictive biomarkers.PMID 21125676Read ↗

The current state of the art and future trends in RAS-targeted cancer therapies.Semantic proximity Read ↗

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.Semantic proximity Read ↗

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Semantic proximity Read ↗

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.Semantic proximity Read ↗

Emerging RAS-directed therapies for cancerSemantic proximity Read ↗

KRAS Mutations in Cancer: From Molecular Insights to Therapeutic Strategies.Semantic proximity Read ↗

Targeting KRAS in Cancer: Promising Therapeutic StrategiesSemantic proximity Read ↗

Targeting Mutated KRAS Genes to Treat Solid Tumours.Semantic proximity Read ↗

Biology, pathology, and therapeutic targeting of RAS.Semantic proximity Read ↗

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.Semantic proximity Read ↗

Past, Present, and Future of Targeting Ras for Cancer Therapies.Semantic proximity Read ↗

Therapeutics Targeting Mutant KRAS.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.